Genprex Partners with MD Anderson to Study TROP2, PTEN Biomarkers for Reqorsa Trials
Genprex has signed a Sponsored Research Agreement with UT MD Anderson to study biomarkers TROP2 and PTEN that may predict patient response to its lead gene therapy candidate, Reqorsa, in non-small cell and small cell lung cancer. Preclinical data indicate these markers could refine patient selection in its Acclaim-1 and Acclaim-3 trials.
1. Research Agreement Details
Genprex entered a Sponsored Research Agreement with UT MD Anderson Cancer Center to study TROP2 and PTEN biomarkers for predicting response to its lead gene therapy, Reqorsa. This expands their decade-long collaboration and underscores a tailored oncology approach.
2. Biomarker Significance
Preclinical studies identified TROP2, a tumor-associated glycoprotein, and PTEN, a tumor suppressor gene, as potential indicators of enhanced efficacy for Reqorsa treatment. Their validation could enable more precise patient targeting.
3. Clinical Trial Implications
Results from Acclaim-1 (NSCLC) and Acclaim-3 (SCLC) trials could be enriched by selecting biomarker-positive patients, potentially improving response rates and progression-free survival. Both trials are in Phase 2 expansion following encouraging Phase 1 safety and early efficacy signals.
4. Strategic Impact on Genprex
Successful biomarker validation may accelerate regulatory discussions, boost trial efficiency, and enhance the company’s precision oncology profile, potentially driving greater investor confidence in Genprex’s pipeline and valuation.